The Trust's Clinical Trials Accelerator Platform receives funding from the Cystic Fibrosis Foundation for the next five years

We are delighted to announce that our Clinical Trials Accelerator Platform (CTAP) has been awarded £5.2m of funding for the next five years from the USA’s Cystic Fibrosis Foundation. CTAP is a UK-wide initiative bringing together NHS cystic fibrosis centres to support people with CF to access and participate in CF clinical trials.

Since the programme launch in 2017, we have brought together 27 CF centres across the UK, funded a national team of 25 Trial Coordinators, supported the setup of six early phase research centres and developed resources and information on our Clinical Trials Hub about taking part in clinical trials.

This new funding means that we can continue to grow the CTAP programme to ensure the UK remains a global leader in delivering a broad range of clinical trials developing a variety of new therapies for CF.

Clinical trials are the crucial and significant step in between new medicines being developed in the lab and becoming available for prescription by a doctor. They’re the only way to evaluate whether a new treatment is both safe and effective for use in people – without clinical trials, none of the medications available today, including new modulators, would be available.

We know that new modulators don’t work for everyone, and we know that they are not a cure. We’re at the forefront of innovation and progress. Boundaries will be broken by groundbreaking research and clinical trials as we find discoveries that will change lives for the CF community for the better.

Jess Longmate, Head of Clinical Trials Accelerator Platform at the Trust, said: 

"This funding will enable us to expand the CTAP coordinating team and introduce further support and infrastructure of our 27 CTAP centres. It’s fantastic news that we have acquired this additional funding as there is still work to be done in the fight for a life unlimited for everyone with CF. These additional resources will be hugely beneficial in opening new trials in the UK and developing new therapies in a range of CF-related areas."

Stronger together. United and unstoppable. Together, we’re uniting for a life unlimited.

If you’d like to get involved with a clinical trial, why not take a look at our CF Trials Tracker and find one that’s right for you?

Stay in touch to hear about clinical trials and ways you can help us pave the way for transformative new treatments by signing up to our quarterly clinical trials newsletter.

Cystic fibrosis (CF) is a genetic condition which causes sticky mucus to build up in the lungs and digestive system. It affects more than 10,800 people in the UK. One in 25 of us carries the faulty gene that causes it, usually without knowing. 

Your donations help us fund vital research. Donate today to help everyone with CF live a life unlimited. 

Donate now